List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4760893/publications.pdf Version: 2024-02-01

		6613	11607
574	24,851	79	135
papers	citations	h-index	g-index
611	611	611	12723
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Implantation of one, two or multiple MitraClipâ,,¢ for transcatheter mitral valve repair: insights from a 1824-patient multicenter study. Panminerva Medica, 2022, 64, .	0.8	6
2	Ultrasound- Versus Fluoroscopy-Guided Femoral Access for Percutaneous Coronary Intervention of Chronic Total Occlusions: Insights From FOUND BLOOD CTO Registry. Cardiovascular Revascularization Medicine, 2022, 38, 61-67.	0.8	5
3	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. International Journal of Cardiology, 2022, 349, 31-38.	1.7	4
4	Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from the multi-center MITRA-TUNE registry. International Journal of Cardiology, 2022, 349, 39-45.	1.7	16
5	Predictors of optimal procedural result after transcatheter edgeâ€toâ€edge mitral valve repair in secondary mitral regurgitation. Catheterization and Cardiovascular Interventions, 2022, 99, 1626-1635.	1.7	11
6	Transcatheter aortic valve implantation during COVID-19 pandemic: An optimized model to relieve healthcare system overload. International Journal of Cardiology, 2022, 352, 190-194.	1.7	3
7	Usefulness of intravascular ultrasound to assess coronary occlusion after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	3
8	One-Year Outcomes and Trends over Two Eras of Transcatheter Aortic Valve Implantation in Real-World Practice. Journal of Clinical Medicine, 2022, 11, 1164.	2.4	1
9	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	3.7	5
10	Clinical outcomes of suboptimal stent deployment as assessed by optical coherence tomography: long-term results of the CLI-OPCI registry. EuroIntervention, 2022, 18, e150-e157.	3.2	7
11	Sinus of Valsalva Sequestration Following Transcatheter-Based Management of ACURATE neo2 Valve Embolization. JACC: Cardiovascular Interventions, 2022, 15, 1179-1180.	2.9	1
12	Transcatheter Aortic Valve Replacement With Self-Expanding ACURATE neo2. JACC: Cardiovascular Interventions, 2022, 15, 1101-1110.	2.9	17
13	Realâ€world experience with the new Watchman FLX device: Data from two highâ€volume Sicilian centers. The FLXâ€iEST registry. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	6
14	Clinical outcomes and predictors in patients with previous cardiac surgery undergoing mitral valve transcatheter edgeâ€toâ€edge repair. Catheterization and Cardiovascular Interventions, 2022, 100, 451-460.	1.7	4
15	Edgeâ€ŧoâ€edge percutaneous mitral repair for functional ischaemic and nonâ€ischaemic mitral regurgitation: a systematic review and metaâ€analysis. ESC Heart Failure, 2022, 9, 3177-3187.	3.1	5
16	Predictors of early discharge after transcatheter aortic valve implantation: insight from the CoreValve ClinicalService. Journal of Cardiovascular Medicine, 2022, 23, 454-462.	1.5	4
17	Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial. American Heart Journal, 2021, 232, 23-38.	2.7	28
18	Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems International Journal of Cardiology, 2021, 327, 209-216.	1.7	9

#	Article	IF	CITATIONS
19	Does the left circumflex coronary artery location impact on the success of chronic total occlusion recanalization? A single-center cohort study. Scandinavian Cardiovascular Journal, 2021, 55, 106-108.	1.2	2
20	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. International Journal of Cardiology, 2021, 325, 109-114.	1.7	19
21	Prevalence and morphological changes of carotid kinking and coiling in growth: an echo-color Doppler study of 2856 subjects between aged 0 to 96Âyears. International Journal of Cardiovascular Imaging, 2021, 37, 479-484.	1.5	5
22	Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Clinical Research in Cardiology, 2021, 110, 667-675.	3.3	8
23	A novel, comprehensive tool for predicting 30-day mortality after surgical aortic valve replacement. European Journal of Cardio-thoracic Surgery, 2021, 59, 586-592.	1.4	6
24	Italian Society of Interventional Cardiology (<scp>Glse</scp>) registry Of Transcatheter treatment of mitral valve r <scp>egurgitaTiOn</scp> (<scp>GIOTTO</scp>): impact of valve disease aetiology and residual mitral regurgitation after <scp>MitraClip</scp> implantation. European Journal of Heart Failure, 2021, 23, 1364-1376.	7.1	49
25	Longâ€ŧerm outcomes of selfâ€expanding versus balloonâ€expandable transcatheter aortic valves: Insights from the OBSERVANT study. Catheterization and Cardiovascular Interventions, 2021, 98, 1167-1176.	1.7	3
26	MitraClip After Failed Surgical Mitral Valve Repair—An International Multicenter Study. Journal of the American Heart Association, 2021, 10, e019236.	3.7	8
27	Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI – The TRITAVI-Women Study. International Journal of Cardiology, 2021, 333, 69-76.	1.7	7
28	Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli. JACC: Cardiovascular Interventions, 2021, 14, 1218-1228.	2.9	40
29	One-Year Outcomes after Surgical versus Transcatheter Aortic Valve Replacement with Newer Generation Devices. Journal of Clinical Medicine, 2021, 10, 3703.	2.4	8
30	Characteristics and outcomes of MitraClip in octogenarians: Evidence from 1853 patients in the GIOTTO registry. International Journal of Cardiology, 2021, 342, 65-71.	1.7	8
31	Impact of Post-Procedural Change in Left Ventricle Systolic Function on Survival after Percutaneous Edge-to-Edge Mitral Valve Repair. Journal of Clinical Medicine, 2021, 10, 4748.	2.4	5
32	An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation. EuroIntervention, 2021, 17, 728-735.	3.2	8
33	Long-term outcomes after transcatheter aortic valve replacement in nonagenarians: a multicenter age-based analysis. Journal of Cardiovascular Medicine, 2021, 22, 204-211.	1.5	2
34	Relationship between <i>c</i> oronary p <i>l</i> aque morphology of the left anter <i>i</i> or descending artery and 12 <i>m</i> onths clinic <i>a</i> l outcome: the CLIMA study. European Heart Journal, 2020, 41, 383-391.	2.2	250
35	Factors influencing the choice between transcatheter and surgical treatment of severe aortic stenosis in patients younger than 80 years: Results from the OBSERVANT study. Catheterization and Cardiovascular Interventions, 2020, 95, E186-E195.	1.7	26
36	Prospective evaluation of drug eluting selfâ€apposing stent for the treatment of unprotected left main coronary artery disease: 1â€year results of the TRUNC study. Catheterization and Cardiovascular Interventions, 2020, 96, E142-E148.	1.7	4

#	Article	IF	CITATIONS
37	EDITORIAL: 'Coapting' Clinical Evidence on Mortality Impact of MitraClip Implantation in Patients with Functional Mitral Regurgitation. Cardiovascular Revascularization Medicine, 2020, 21, 61-62.	0.8	1
38	Outcomes of three different new generation transcatheter aortic valve prostheses. Catheterization and Cardiovascular Interventions, 2020, 95, 398-407.	1.7	28
39	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (Glse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovascular Revascularization Medicine, 2020, 21, 1057-1062.	0.8	23
40	Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in SmallÂAortic Annuli. JACC: Cardiovascular Interventions, 2020, 13, 196-206.	2.9	54
41	Percutaneous Edge-to-Edge Mitral Valve Repair with the Mitraclip System in Barlow's Disease. Structural Heart, 2020, 4, 139-142.	0.6	0
42	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. Cardiovascular Revascularization Medicine, 2020, 21, 857-864.	0.8	5
43	Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. European Heart Journal, 2020, 41, 1876-1886.	2.2	45
44	Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis. Circulation, 2020, 142, 2431-2442.	1.6	96
45	Coronary Cannulation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2542-2555.	2.9	118
46	Prespecified Risk Criteria Facilitate Adequate Discharge and Longâ€Term Outcomes After Transfemoral Transcatheter Aortic Valve Implantation. Journal of the American Heart Association, 2020, 9, e016990.	3.7	8
47	Predictors of Outcomes Following Transcatheter Edge-to-Edge MitralÂValveÂRepair. JACC: Cardiovascular Interventions, 2020, 13, 1733-1748.	2.9	20
48	First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study. International Journal of Cardiology, 2020, 321, 48-53.	1.7	1
49	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	3.9	17
50	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. Journal of the American College of Cardiology, 2020, 75, 1882-1893.	2.8	140
51	Transcatheter aortic valve implantation: how to decrease post-operative complications. European Heart Journal Supplements, 2020, 22, E148-E152.	0.1	4
52	Early and late outcomes after transcatheter versus surgical aortic valve replacement in obese patients. Archives of Medical Science, 2020, 16, 796-801.	0.9	7
53	Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project. Catheterization and Cardiovascular Interventions, 2020, 96, 1500-1508.	1.7	8
54	Balloon Versus Self-Expandable Valve for the Treatment of Bicuspid Aortic Valve Stenosis. Circulation: Cardiovascular Interventions, 2020, 13, e008714.	3.9	62

#	Article	IF	CITATIONS
55	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). American Journal of Cardiology, 2020, 125, 1369-1377.	1.6	15
56	Female sex impact on culprit plaque at optical coherence tomography analysis in the setting of acute coronary syndrome in OCT-FORMIDABLE registry. Future Cardiology, 2020, 16, 123-131.	1.2	3
57	When antegrade microcatheter does not follow: The "facilitated tipâ€in techniqueâ€. Catheterization and Cardiovascular Interventions, 2020, 96, E458-E461.	1.7	4
58	Coronary Protection to Prevent Coronary Obstruction During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 739-747.	2.9	58
59	Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience. Coronary Artery Disease, 2020, 31, 27-34.	0.7	0
60	Severe aortic valve stenosis: Symptoms, biochemical markers, and global longitudinal strain. Journal of Cardiovascular Echography, 2020, 30, 154.	0.4	4
61	PCR Valves e-Course 2020: lifelong learning never stops. PCR London Valves goes virtual!. EuroIntervention, 2020, 16, 783.	3.2	0
62	Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in a Real World Population. Circulation: Cardiovascular Interventions, 2019, 12, e007825.	3.9	46
63	Oral Anticoagulant Type and OutcomesÂAfter Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 1566-1576.	2.9	90
64	Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. American Heart Journal, 2019, 217, 32-41.	2.7	50
65	Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. Expert Review of Cardiovascular Therapy, 2019, 17, 479-496.	1.5	9
66	Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. International Journal of Cardiovascular Imaging, 2019, 35, 1767-1776.	1.5	5
67	Antithrombotic Therapy in Transcatheter Aortic Valve Replacement. Frontiers in Cardiovascular Medicine, 2019, 6, 73.	2.4	1
68	Long-Term Outcomes in Patients With New-Onset Persistent Left Bundle Branch Block Following TAVR. JACC: Cardiovascular Interventions, 2019, 12, 1175-1184.	2.9	60
69	Coronary lithotripsy for failed rotational atherectomy, cutting balloon, scoring balloon, and ultraâ€highâ€pressure nonâ€compliant balloon. Catheterization and Cardiovascular Interventions, 2019, 94, E111-E115.	1.7	19
70	Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study. Canadian Journal of Cardiology, 2019, 35, 866-874.	1.7	4
71	Transcatheter Aortic Valve ReplacementÂWith Next-Generation Self-Expanding Devices. JACC: Cardiovascular Interventions, 2019, 12, 433-443.	2.9	59
72	Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006841.	4.8	199

#	Article	IF	CITATIONS
73	Incidence, Technical Safety, and Feasibility of Coronary Angiography and Intervention Following Self-expanding Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2019, 20, 371-375.	0.8	29
74	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	1.7	4
75	Selfâ€expandable sirolimusâ€eluting stents compared to secondâ€generation drugâ€eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILSâ€2 registries. Catheterization and Cardiovascular Interventions, 2019, 93, 208-215.	1.7	1
76	Long-term Transcatheter Aortic Valve Durability. Interventional Cardiology Review, 2019, 14, 62-69.	1.6	26
77	Pacemaker dependency after transcatheter aortic valve implantation: incidence, predictors and long-term outcomes. EuroIntervention, 2019, 15, 875-883.	3.2	74
78	Degeneration of prosthesis after transcatheter aortic valve implantation. Minerva Cardioangiologica, 2019, 67, 57-63.	1.2	3
79	Self-Expanding vs. Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation. , 2019, , 305-328.		0
80	2019 – A leap year for valvular heart disease. EuroIntervention, 2019, 15, 821-823.	3.2	0
81	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
82	Optimization and simplification of transcatheter aortic valve implantation therapy. Expert Review of Cardiovascular Therapy, 2018, 16, 287-296.	1.5	12
83	Impact of Incomplete Revascularization on Long-Term Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 121, 1138-1148.	1.6	16
84	Transcatheter aortic valve implantation compared with surgical aortic valve replacement in patients with anaemia. Acta Cardiologica, 2018, 73, 50-59.	0.9	4
85	Feasibility and Outcomes of Repeat Percutaneous Edge-to-Edge Mitral Valve Repair Procedures in Patients at High Risk forÂSurgery. JACC: Cardiovascular Interventions, 2018, 11, 818-820.	2.9	1
86	Meta-Analysis Comparing Single Versus Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 122, 310-315.	1.6	61
87	TAVI Postprocedural Management. , 2018, , 483-499.		0
88	Clinical performance of a dedicated self-apposing stent for the treatment of left main stem disease. Results of the left Main AngioplasTy wIth a Self-apposing StEnt - the MATISSE study. Cardiovascular Revascularization Medicine, 2018, 19, 831-836.	0.8	5
89	Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System. American Journal of Cardiology, 2018, 121, 1253-1259.	1.6	15
90	Long-Term Outcomes in Patients WithÂNew Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 301-310.	2.9	130

#	Article	IF	CITATIONS
91	Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation, 2018, 137, 2435-2445.	1.6	116
92	Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: A multicenter registry. International Journal of Cardiology, 2018, 258, 36-41.	1.7	7
93	Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device. Structural Heart, 2018, 2, 229-234.	0.6	1
94	Non-Contrast Three-Dimensional Magnetic Resonance Imaging for Pre-Procedural Assessment of Aortic Annulus Dimensions in Patients Undergoing Transcatheter Aortic Valve Implantation. Structural Heart, 2018, 2, 247-249.	0.6	0
95	Long-Term Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients Who Have Undergone Coronary Artery Bypass Grafting vs Those Who Have Not. Canadian Journal of Cardiology, 2018, 34, 310-318.	1.7	38
96	Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds. Circulation: Cardiovascular Interventions, 2018, 11, e005768.	3.9	10
97	Updated clinical indications for transcatheter aortic valve implantation in patients with severe aortic stenosis: expert opinion of the Italian Society of Cardiology and GISE. Journal of Cardiovascular Medicine, 2018, 19, 197-210.	1.5	28
98	Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2018, 71, 1513-1524.	2.8	170
99	Clinical Outcomes and Prognosis Markers of Patients With Liver Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e005727.	3.9	36
100	Culprit plaque characteristics in younger versus older patients with acute coronary syndromes: An optical coherence tomography study from the FORMIDABLE registry. Catheterization and Cardiovascular Interventions, 2018, 92, E1-E8.	1.7	9
101	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <scp>E</scp> uropean <scp>M</scp> ulticentre <scp>GHOST</scp> â€ <scp>EU</scp> <scp>R</scp> egistry. Catheterization and Cardiovascular Interventions. 2018. 91, 444-453.	1.7	8
102	Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry. International Journal of Cardiology, 2018, 253, 45-49.	1.7	7
103	Longâ€ŧerm clinical and echocardiographic outcomes of Mitraclip therapy in patients nonresponders to cardiac resynchronization. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 65-72.	1.2	9
104	Impact of Preexisting Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients. Circulation: Cardiovascular Interventions, 2018, 11, e006927.	3.9	26
105	Lipid Plaque Modification DuringÂResorption of Absorb Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2018, 11, 2123-2124.	2.9	3
106	Incidence of Longâ€īerm Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement. Journal of the American Heart Association, 2018, 7, e008440.	3.7	80
107	Comparison of Early and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with New York Heart Association Functional Class IV to those in Class III and Less. American Journal of Cardiology, 2018, 122, 1718-1726.	1.6	8
108	The Learning Curve and Annual Procedure VolumeÂStandards for Optimum Outcomes of Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1669-1679.	2.9	82

#	Article	IF	CITATIONS
109	In vivo vulnerability grading system of plaques causing acute coronary syndromes: An intravascular imaging study. International Journal of Cardiology, 2018, 269, 350-355.	1.7	16
110	Recanalization of Chronic Total Occlusions in Patients With vs Without Chronic Kidney Disease: The Impact of Contrast-Induced Acute Kidney Injury. Canadian Journal of Cardiology, 2018, 34, 1275-1282.	1.7	36
111	17â€Impact of incomplete revascularisation on long-term outcomes following chronic total occlusion percutaneous coronary intervention. , 2018, , .		0
112	Clinical impact of optical coherence tomography findings on culprit plaque in acute coronary syndrome: The OCTâ€FORMIDABLE study registry. Catheterization and Cardiovascular Interventions, 2018, 92, E486-E492.	1.7	7
113	Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: A comparative analysis from the Italian OBSERVANT study. International Journal of Cardiology, 2018, 270, 102-106.	1.7	32
114	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp> â€ <scp>EU</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 92, 276-282.	1.7	4
115	Early recovery of left ventricular systolic function after transcatheter aortic valve implantation. Journal of Cardiovascular Echography, 2018, 28, 166.	0.4	8
116	Morpho-functional cardiovascular adaptation in hypertensive patients: two-dimensional speckle tracking echocardiographic study. Minerva Cardiology and Angiology, 2018, 66, 368-375.	0.7	0
117	Appraisal of key trials in aortic and mitral fields. EuroIntervention, 2018, 14, AB19-AB32.	3.2	0
118	Transcatheter aortic valve replacement in nonagenarians: early and intermediate outcome from the OBSERVANT study and meta-analysis of the literature. Heart and Vessels, 2017, 32, 157-165.	1.2	25
119	Multimodality imaging of a left main coronary artery-to-pulmonary artery fistula. Journal of Cardiovascular Medicine, 2017, 18, 704-705.	1.5	1
120	Pathophysiology, incidence and predictors of conduction disturbances during Transcatheter Aortic Valve Implantation. Expert Review of Medical Devices, 2017, 14, 135-147.	2.8	25
121	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, 560-568.	2.9	16
122	A propensity score matched comparative study between paclitaxelâ€coated balloon and everolimusâ€eluting stents for the treatment of small coronary vessels. Catheterization and Cardiovascular Interventions, 2017, 90, 380-386.	1.7	23
123	A Risk Model for Prediction of 1-Year Mortality in Patients Undergoing MitraClip Implantation. American Journal of Cardiology, 2017, 119, 1443-1449.	1.6	31
124	Feasibility and predictors of early discharge after percutaneous edge-to-edge mitral valve repair. Heart, 2017, 103, 931-936.	2.9	7
125	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2017, 166, 606.	3.9	1
126	Strategies and Outcomes of Repeat Mitral Valve Interventions after Failed MitraClip Therapy. Cardiology, 2017, 137, 114-120.	1.4	6

#	Article	IF	CITATIONS
127	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	63
128	Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study. Clinical Research in Cardiology, 2017, 106, 784-795.	3.3	21
129	Evaluation of current practices in transcatheter aortic valve implantation: The WRITTEN (WoRldwIde) Tj ETQq1 1	0.784314 1.7	rgBT /Overlo
130	Effect of valve design and anticoagulation strategy on 30â€day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	1.7	4
131	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
132	Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. European Heart Journal, 2017, 38, 2729-2738.	2.2	56
133	Optical coherence tomography compared with fractional flow reserve guided approach in acute coronary syndromes: A propensity matched analysis. International Journal of Cardiology, 2017, 244, 54-58.	1.7	11
134	Unusual interatrial membrane in the left atrium: A newer obstacle for transseptalâ€based percutaneous mitral valve repair techniques?. Echocardiography, 2017, 34, 1379-1381.	0.9	0
135	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	2.9	1
136	Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus TricuspidÂAorticÂValve Stenosis. Journal of the American College of Cardiology, 2017, 69, 2579-2589.	2.8	356
137	Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLEâ€CARDIOGROUP IV and USZ registry. Catheterization and Cardiovascular Interventions, 2017, 90, E46-E52.	1.7	26
138	Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients – results from the BELLO (balloon elution and late loss) Tj ETQq0 0 0 rgBT	/000.erlock	102Tf 50 297
139	Biologic prosthetic aortic malfunction. Journal of Cardiovascular Medicine, 2017, 18, e170-e176.	1.5	0
140	Hot topics in transcatheter aortic valve implantation. Future Cardiology, 2017, 13, 503-506.	1.2	1
141	Transcatheter Mitral Valve Implantation Using the HighLife System. JACC: Cardiovascular Interventions, 2017, 10, 1662-1670.	2.9	44
142	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	2.9	26
143	Clinical Impact of Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1564-1574.	2.9	87
144	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2017, 38, 3382-3390.	2.2	335

#	Article	IF	CITATIONS
145	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Journal of Cardiothoracic Surgery, 2017, 52, 408-417.	1.4	160
146	Institutional experience and outcomes of transcatheter aortic valve replacement: Results from an international multicentre registry. International Journal of Cardiology, 2017, 245, 222-227.	1.7	6
147	Transcatheter aortic valve replacement with new-generation devices: A systematic review and meta-analysis. International Journal of Cardiology, 2017, 245, 83-89.	1.7	100
148	Transcatheter aortic valve implantation with a mechanical-expandable device: when perfection is hung on a â€~wire'. European Heart Journal, 2017, 38, 3367-3369.	2.2	1
149	Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	25
150	HbA1c Identifies Subjects With Prediabetes and Subclinical Left Ventricular Diastolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3756-3764.	3.6	44
151	Prognostic Significance of Change in the Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Left Ventricular Dysfunction. American Journal of Cardiology, 2017, 120, 1639-1647.	1.6	12
152	Clinical Outcomes Following IntravascularÂImaging-Guided Versus Coronary Angiography–Guided Percutaneous Coronary Intervention WithÂStent Implantation. JACC: Cardiovascular Interventions, 2017, 10, 2488-2498.	2.9	209
153	Acute and long-term (2-years) clinical outcomes of the CoreValve 31 mm in large aortic annuli: A multicenter study. International Journal of Cardiology, 2017, 227, 543-549.	1.7	11
154	Impact of overlapping on 1â€year clinical outcomes in patients undergoing everolimusâ€eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOSTâ€EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 812-818.	1.7	15
155	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 47-56.	1.7	28
156	Procedural Management of Patients With Advanced Heart Failure Undergoing MitraClip Implantation (From the GRASP Registry). Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, e6-e8.	1.3	11
157	Feasibility and safety of early discharge after transfemoral transcatheter aortic valve implantation – rationale and design of the FAST-TAVI registry. BMC Cardiovascular Disorders, 2017, 17, 259.	1.7	19
158	Transcathether aortic valve implantation with the new repositionable self-expandable Evolut R versus CoreValve system: A case-matched comparison. International Journal of Cardiology, 2017, 243, 126-131.	1.7	37
159	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
160	A membranous septal aneurysm causing right ventricular outflow tract obstruction in an adult. Journal of Cardiovascular Echography, 2017, 27, 145.	0.4	4
161	Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts. Canadian Journal of Cardiology, 2017, 33, 951.e5-951.e6.	1.7	0
162	Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. Journal of Cardiovascular Medicine, 2016, 17, 843-849.	1.5	9

#	Article	IF	CITATIONS
163	Everolimusâ€eluting bioresorbable vascular scaffolds versus second generation drugâ€eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the G <scp>HOSTâ€CTO</scp> registry. Catheterization and Cardiovascular Interventions, 2016, 88, E155-E163.	1.7	11
164	A Bicuspid Aortic Valve Imaging ClassificationÂforÂthe TAVR Era. JACC: Cardiovascular Imaging, 2016, 9, 1145-1158.	5.3	174
165	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. Annals of Internal Medicine, 2016, 165, 334.	3.9	102
166	Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients. Evidence-Based Medicine, 2016, 21, 173-173.	0.6	0
167	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. International Journal of Cardiology, 2016, 209, 153-160.	1.7	37
168	Reply. Journal of the American College of Cardiology, 2016, 67, 1381-1382.	2.8	0
169	Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?. JACC: Cardiovascular Interventions, 2016, 9, 976-977.	2.9	0
170	Predictors for Paravalvular Regurgitation AfterÂTAVRÂWith the Self-Expanding Prosthesis: Quantitative Measurement of MDCT Analysis. JACC: Cardiovascular Imaging, 2016, 9, 1233-1234.	5.3	7
171	Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Low-Risk Patients. Circulation: Cardiovascular Interventions, 2016, 9, e003326.	3.9	100
172	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages 3b to 5. Annals of Thoracic Surgery, 2016, 102, 540-547.	1.3	32
173	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. International Journal of Cardiology, 2016, 203, 264-266.	1.7	24
174	Bicuspid Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2016, 9, 817-824.	2.9	147
175	Outcomes of Redo Transcatheter Aortic Valve Replacement for the Treatment of Postprocedural and Late Occurrence of Paravalvular Regurgitation and Transcatheter Valve Failure. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	83
176	Transcatheter Aortic Valve Replacement With Early- and New-Generation Devices in Bicuspid Aortic Valve Stenosis. Journal of the American College of Cardiology, 2016, 68, 1195-1205.	2.8	177
177	Embolic protection device in a patient with large left ventricular thrombus undergoing transcatheter aortic valve replacement. International Journal of Cardiology, 2016, 222, 703-704.	1.7	2
178	Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry. International Journal of Cardiology, 2016, 224, 440-446.	1.7	19
179	Age-Related Differences in 1- and 12-Month Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation (from a Large Multicenter Data Repository). American Journal of Cardiology, 2016, 118, 1024-1030.	1.6	4
180	MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2016, 102, e517-e519.	1.3	7

#	Article	IF	CITATIONS
181	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
182	Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). European Journal of Cardio-thoracic Surgery, 2016, 50, 1139-1148.	1.4	32
183	Renal dysfunction and transcatheter aortic valve implantation outcomes. Expert Review of Cardiovascular Therapy, 2016, 14, 1315-1323.	1.5	11
184	Predictive ability of the CHADS ₂ and CHA ₂ DS ₂ -VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 867-873.	1.4	11
185	Risk stratification after ST-segment elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2016, 14, 1349-1360.	1.5	5
186	Update on clinical evidence (Part II): A summary of the main post market studies. Catheterization and Cardiovascular Interventions, 2016, 88, 31-37.	1.7	0
187	Risk prediction of contrast-induced nephropathy by ACEF score in patients undergoing coronary catheterization. Journal of Cardiovascular Medicine, 2016, 17, 524-529.	1.5	17
188	Retrograde Approach for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	0
189	Outcome After General Anesthesia Versus Monitored Anesthesia Care in Transfemoral Transcatheter Aortic Valve Replacement. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1238-1243.	1.3	54
190	Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	33
191	Immediate outcome after sutureless versus transcatheter aortic valve replacement. Heart and Vessels, 2016, 31, 427-433.	1.2	48
192	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 475-486.	1.0	15
193	Immediate and Intermediate Outcome After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2016, 117, 245-251.	1.6	100
194	Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face?. Expert Review of Cardiovascular Therapy, 2016, 14, 381-389.	1.5	8
195	Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal, 2016, 37, 2465-2474.	2.2	410
196	Early and Midterm Outcome of Propensity-Matched Intermediate-Risk Patients Aged ≥80 Years With Aortic Stenosis Undergoing Surgical or Transcatheter Aortic Valve Replacement (from the Italian) Tj ETQq0 0 0 1	rgBTL /O ver	locks&0 Tf 50
197	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	2.9	23

198 Embolization of Fractured BioresorbableÂScaffold Struts. JACC: Cardiovascular Interventions, 2016, 9, 2.9 2 e37-e38.

#	Article	IF	CITATIONS
199	Impact of Anesthesia Type on Outcomes of Transcatheter Aortic Valve Implantation (from the) Tj ETQq1 1 0.784	314 rgBT 1.6	/Overlock 10
200	Three-Year Outcomes of Transcatheter Aortic Valve Implantation in Patients With Varying Levels of Surgical Risk (from the CoreValve ADVANCE Study). American Journal of Cardiology, 2016, 117, 820-827.	1.6	11
201	Prosthesis choice for transcatheter aortic valve replacement: Improved outcomes with the adoption of a patient-specific transcatheter heart valve selection algorithm. International Journal of Cardiology, 2016, 203, 1009-1010.	1.7	7
202	Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture. JACC: Cardiovascular Imaging, 2016, 9, 210-211.	5.3	5
203	Revascularization vs. Optimal Medical Therapy in Women with NSTE-ACS. Current Pharmaceutical Design, 2016, 22, 3905-3914.	1.9	2
204	The failing right heart: implications and evolution in high-risk patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, 1542-1549.	3.2	16
205	STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. EuroIntervention, 2016, 11, e1267-e1274.	3.2	23
206	One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice. EuroIntervention, 2016, 12, e152-e159.	3.2	7
207	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention. 2016. 12. e623-e631.	3.2	17
208	Late degeneration of transcatheter aortic valves: pathogenesis and management. EuroIntervention, 2016, 12, Y33-Y36.	3.2	17
209	Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry. EuroIntervention, 2016, 12, 381-388.	3.2	45
210	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention, 2016, 12, e550-e556.	3.2	32
211	Current Status and Clinical Development of Transcatheter Approaches for Severe Mitral Regurgitation. Circulation Journal, 2015, 79, 1164-1171.	1.6	19
212	Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the <scp>GHOST</scp> registry. Catheterization and Cardiovascular Interventions, 2015, 85, 1150-1161.	1.7	32
213	Multicenter evaluation of transcatheter aortic valve replacement using either <scp>SAPIEN XT</scp> or <scp>C</scp> ore <scp>V</scp> alve: Degree of device oversizing by computedâ€tomography and clinical outcomes. Catheterization and Cardiovascular Interventions, 2015, 86, 508-515.	1.7	60
214	New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length. Catheterization and Cardiovascular Interventions, 2015, 85, E99-E107.	1.7	9
215	The impact of calcium volume and distribution in aortic root injury related to balloon-expandable transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2015, 9, 382-392.	1.3	91
216	Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart, 2015, 101, 1395-1405.	2.9	115

#	Article	IF	CITATIONS
217	Reference Values for Real Time Threeâ€Dimensional Echocardiography–Derived Left Ventricular Volumes and Ejection Fraction: Review and Metaâ€Analysis of Currently Available Studies. Echocardiography, 2015, 32, 1841-1850.	0.9	22
218	Fate of Coronary Chronic Total Occlusion Recanalization via Subintimal Tracking WithÂBioresorbable Vascular Scaffolds: A Temporary Cage for a Permanent New Lumen?. JACC: Cardiovascular Imaging, 2015, 8, 1114-1115.	5.3	0
219	Current developments in drug-eluting stent technologies. Interventional Cardiology, 2015, 7, 225-228.	0.0	0
220	Extended Use of Percutaneous Edge-to-Edge Mitral Valve Repair BeyondÂEVEREST (Endovascular Valve) Tj ETQqC	0.0 rgBT	Overlock 10
221	A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. International Journal of Cardiology, 2015, 184, 17-21.	1.7	51
222	Late Cardiac Death in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 65, 437-448.	2.8	196
223	Optical Coherence Tomography Assessment of Late Intra-Scaffold Dissection. JACC: Cardiovascular Interventions, 2015, 8, e11-e12.	2.9	3
224	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002220.	3.9	73
225	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A metaâ€analysis of 5,971 patients. Catheterization and Cardiovascular Interventions, 2015, 86, 518-527.	1.7	75
226	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	164
227	Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation, 2015, 131, 1566-1574.	1.6	227
228	Five-year outcomes of percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with left main coronary artery disease: An updated meta-analysis of randomized trials and adjusted observational studies. International Journal of Cardiology, 2015, 195, 79-81.	1.7	22
229	Cyphering the Mechanism of Late Failure of Bioresorbable Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2015, 8, e95-e97.	2.9	1
230	Early discharge after transfemoral transcatheter aortic valve implantation. Heart, 2015, 101, 1485-1490.	2.9	80
231	Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. Europace, 2015, 17, 1136-1140.	1.7	30
232	SYNTAX Score II predicts carotid disease in a multivessel coronary disease population. International Journal of Cardiology, 2015, 196, 145-148.	1.7	5
233	One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy?. Canadian Journal of Cardiology, 2015, 31, 1205.e5-1205.e6.	1.7	0

Antiplatelet therapy following transcatheter aortic valve implantation. Heart, 2015, 101, 1118-1125. 2.9 56

#	Article	IF	CITATIONS
235	The Incidence and Predictors of Early- and Mid-Term Clinically Relevant Neurological Events After Transcatheter Aortic Valve Replacement in Real-World Patients. Journal of the American College of Cardiology, 2015, 66, 209-217.	2.8	73
236	5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis. JACC: Cardiovascular Interventions, 2015, 8, 1084-1091.	2.9	184
237	Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. American Heart Journal, 2015, 170, 187-195.	2.7	90
238	Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis Patients Undergoing Chronic Dialysis. Journal of the American College of Cardiology, 2015, 66, 93-94.	2.8	12
239	New-Onset Coronary Aneurism and Late-Acquired Incomplete Scaffold Apposition After Full Polymer Jacket ofÂaÂChronic Total Occlusion With Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2015, 8, e41-e43.	2.9	9
240	Neoatherosclerosis as the Cause of LateÂFailure of a Bioresorbable VascularÂScaffold. JACC: Cardiovascular Interventions, 2015, 8, 633-634.	2.9	11
241	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 189, 77-78.	1.7	5
242	Impact of P2Y12-mediated platelet reactivity on myocardial perfusion of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P152.	3.3	0
243	Balancing the Risk of Bleeding and Stroke in Patients WithÂAtrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	1.6	28
244	Longitudinal Elongation, Axial Compression, and Effects on StrutÂGeometry of Bioresorbable VascularÂScaffolds. JACC: Cardiovascular Interventions, 2015, 8, e35-e37.	2.9	3
245	Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure. Journal of Interventional Cardiology, 2015, 28, 61-68.	1.2	19
246	Meta-Analysis of Comparison Between Self-Expandable and Balloon-Expandable Valves for Patients Having Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 115, 1720-1725.	1.6	14
247	Reply to the letter. Journal of Cardiovascular Medicine, 2015, 16, 73.	1.5	0
248	Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study Design and Rationale. Journal of Cardiovascular Medicine, 2015, 16, 253-258.	1.5	9
249	Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 66, 1639-1640.	2.8	32
250	Carotid thin fluttering bands: A new element of arterial wall remodelling? An ultrasound study. International Journal of Cardiovascular Imaging, 2015, 31, 1393-1400.	1.5	1
251	Managing Bioabsorbable Vascular Scaffold Failure: Combined Scaffold Restenosis and Late-Acquired Coronary Aneurysm Treated With Self-Expandable Stent. Canadian Journal of Cardiology, 2015, 31, 691.e1-691.e3.	1.7	9
252	Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 1595-1604.	2.9	108

#	Article	IF	CITATIONS
253	Comparison of Aortic Root Anatomy and Calcification Distribution Between Asian and Caucasian Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 1566-1573.	1.6	31
254	Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. International Journal of Cardiology, 2015, 201, 276-278.	1.7	3
255	Transcatheter Aortic Valve Implantation Under Angiographic Guidance With and Without Adjunctive Transesophageal Echocardiography. American Journal of Cardiology, 2015, 116, 604-611.	1.6	34
256	1-Year Outcomes After TransfemoralÂTranscatheter or SurgicalÂAortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 804-812.	2.8	161
257	Prevalence of asymptomatic lower limb venous thrombosis in infertile women with thrombophilic disorders. Phlebology, 2015, 30, 449-454.	1.2	0
258	Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation. European Heart Journal, 2015, 36, 3370-3379.	2.2	133
259	Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes. Journal of the American College of Cardiology, 2015, 66, 221-228.	2.8	183
260	3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO). JACC: Cardiovascular Interventions, 2015, 8, 1132-1134.	2.9	74
261	Clinical Impact of OCT Findings During PCI. JACC: Cardiovascular Imaging, 2015, 8, 1297-1305.	5.3	255
262	Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ, The, 2015, 351, h5392.	6.0	102
263	Comparison of Three Contemporary Surgical Scores for Predicting All-Cause Mortality of Patients Undergoing Percutaneous Mitral Valve Repair With the MitraClip System (from the Multicenter) Tj ETQq1 1 0.78	431 1.4 rgBT	/@verlock 1
264	Genderâ€related clinical and echocardiographic outcomes at 30â€day and 12â€month follow up after <scp>M</scp> itra <scp>C</scp> lip implantation in the <scp>GRASP</scp> registry. Catheterization and Cardiovascular Interventions, 2015, 85, 889-897.	1.7	44
265	Myocardial deformational adaptations to different forms of training: a real-time three-dimensional speckle tracking echocardiographic study. Heart and Vessels, 2015, 30, 386-395.	1.2	13
266	Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. EuroIntervention, 2015, 11, 690-697.	3.2	48
267	Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention, 2015, 11, 710-717.	3.2	31
268	Bioresorbable vascular scaffolds in left main coronary artery disease. EuroIntervention, 2015, 11, V135-V138.	3.2	5
269	Lessons from the GHOST-EU registry. EuroIntervention, 2015, 11, V170-V174.	3.2	17
270	Treatment of bioresorbable scaffold failure. EuroIntervention, 2015, 11, V175-V180.	3.2	7

#	Article	IF	CITATIONS
271	Optimisation of TAVI: is it mature enough to be defined as a PCI-like procedure?. EuroIntervention, 2015, 14, W110-W113.	3.2	8
272	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention, 2015, 10, 1144-1153.	3.2	411
273	One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). EuroIntervention, 2015, 10, 1261-1266.	3.2	5
274	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
275	Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention, 2015, 11, 885-894.	3.2	14
276	Valvular heart disease: the unanswered questions. EuroIntervention, 2015, 14, W11-W13.	3.2	1
277	Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. Reviews in Cardiovascular Medicine, 2015, 16, 131-9.	1.4	0
278	Three-Dimensional Angle Assessment and Plaque Distribution Classification in Left Main Disease: Impact of Geometry on Outcome. Reviews in Cardiovascular Medicine, 2015, 16, 131-139.	1.4	0
279	Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart, 2014, 1, e000155.	2.3	33
280	Non-Hemodynamically Significant Renal Artery Stenosis Predicts Cardiovascular Events in Persons with Ischemic Heart Disease. American Journal of Nephrology, 2014, 40, 468-477.	3.1	13
281	Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. European Heart Journal Cardiovascular Imaging, 2014, 15, 1246-1255.	1.2	125
282	Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. European Heart Journal, 2014, 35, 2672-2684.	2.2	197
283	Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2014, 12, 1185-1203.	1.5	23
284	Impact on Prognosis of Periprocedural Bleeding after TAVI: Midâ€Term Followâ€Up of a Multicenter Prospective Study. Journal of Interventional Cardiology, 2014, 27, 293-299.	1.2	36
285	Usefulness and Validation of the Survival posT TAVI Score for SurvivalÂAfter Transcatheter Aortic Valve Implantation forÂAortic Stenosis. American Journal of Cardiology, 2014, 114, 1867-1874.	1.6	30
286	Transcatheter Aortic Valve Replacement inÂBicuspid Aortic Valve Disease. Journal of the American College of Cardiology, 2014, 64, 2330-2339.	2.8	280
287	The SYNTAX score does not predict presence of carotid disease in a multivessel coronary disease population. Catheterization and Cardiovascular Interventions, 2014, 83, 1169-1175.	1.7	12
288	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. Journal of Cardiovascular Medicine, 2014, 15, 173-188.	1.5	9

#	Article	IF	CITATIONS
289	Positive airway pressure in patients with coronary artery disease and obstructive sleep apnea syndrome. Journal of Cardiovascular Medicine, 2014, 15, 402-406.	1.5	21
290	Bioprosthetic Valves for Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2014, 312, 843.	7.4	0
291	Impact of Diabetes Mellitus on Early and Midterm Outcomes After Transcatheter Aortic Valve Implantation (from a Multicenter Registry). American Journal of Cardiology, 2014, 113, 529-534.	1.6	52
292	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for LefT main) Tj ETQq0 0 0 rg	BTL ∕ ©verlo	c l⊉å 0 Tf 50 (
293	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45
294	CABG versus PCI in diabetic patients with multivessel disease after risk stratification by the SYNTAX score: A pooled analysis of the SYNTAX and FREEDOM trials. International Journal of Cardiology, 2014, 173, 548-549.	1.7	5
295	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq1 1 Cardiology, 2014, 113, 1348-1355.	0.784314 1.6	rgBT /Overl
296	Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. Journal of Cardiovascular Translational Research, 2014, 7, 82-90.	2.4	5
297	Early cardiovascular remodelling in Fabry disease. Journal of Inherited Metabolic Disease, 2014, 37, 109-116.	3.6	14
298	To kiss or not to kiss? Impact of final kissing-balloon inflation on early and long-term results of percutaneous coronary intervention for bifurcation lesions. Heart and Vessels, 2014, 29, 732-742.	1.2	28
299	Effect of severe left ventricular systolic dysfunction on hospital outcome after transcatheter aortic valve implantation or surgical aortic valve replacement: Results from a propensity-matched population of the Italian OBSERVANT multicenter study. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 568-575.	0.8	24
300	Volumeâ€ŧo reatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: Implications of varying definitions of contrastâ€induced nephropathy. Catheterization and Cardiovascular Interventions, 2014, 83, 907-912.	1.7	21
301	Spontaneous coronary artery dissection. International Journal of Cardiology, 2014, 175, 8-20.	1.7	82
302	Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation. Circulation, 2014, 129, 1233-1243.	1.6	265
303	Subclavian transectional stent fracture and migration to the aortic carrefour: A case description of retrieval by snare system. Catheterization and Cardiovascular Interventions, 2014, 83, 1010-1013.	1.7	0
304	Acute Left Atrial Spontaneous Echocardiographic Contrast and Suspicious Thrombus Formation Following Mitral Regurgitation Reduction With the MitraClip System. JACC: Cardiovascular Interventions, 2014, 7, 1322-1323.	2.9	11
305	TAVR-Associated ProstheticÂValve InfectiveÂEndocarditis. Journal of the American College of Cardiology, 2014, 64, 2176-2178.	2.8	82
306	Late MitraClip procedure after left atrial appendage occlusion. Catheterization and Cardiovascular Interventions, 2014, 83, 291-296.	1.7	0

#	Article	IF	CITATIONS
307	Percutaneous Mitral Valve Edge-to-Edge Repair. Journal of the American College of Cardiology, 2014, 64, 875-884.	2.8	398
308	Clinical Impact of Aortic RegurgitationÂAfter Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 1022-1032.	2.9	91
309	A Gender Based Analysis of Predictors of All Cause Death After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1269-1274.	1.6	50
310	Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. European Heart Journal, 2014, 35, 2685-2696.	2.2	130
311	Early changes of left ventricular geometry and deformational analysis in obese subjects without cardiovascular risk factors: a three-dimensional and speckle tracking echocardiographic study. International Journal of Cardiovascular Imaging, 2014, 30, 1037-1047.	1.5	20
312	Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition. Journal of the American College of Cardiology, 2014, 63, 1355-1367.	2.8	109
313	Catheter-Based Edge-to-Edge Mitral Valve Repair After Percutaneous Mitral Valve Annuloplasty Failure. JACC: Cardiovascular Interventions, 2014, 7, e85-e86.	2.9	12
314	Impact of Balloon Post-Dilation on ClinicalÂOutcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis. JACC: Cardiovascular Interventions, 2014, 7, 1014-1021.	2.9	47
315	Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: Results of the multicenter Italian OBSERVANT Registry. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1529-1539.	0.8	92
316	Peri-procedural outcome of series of 104 carotid artery stenting procedures. Egyptian Heart Journal, 2014, 66, 163-170.	1.2	0
317	A Simple Risk Tool (the OBSERVANT Score) for Prediction of 30-Day Mortality After Transcatheter Aortic Valve Replacement. American Journal of Cardiology, 2014, 113, 1851-1858.	1.6	126
318	Percutaneous Mitral Valve Repair With the MitraClip System for Severe Mitral Regurgitation in Patients With Surgical Mitral Valve Repair Failure. Journal of the American College of Cardiology, 2014, 63, 836-838.	2.8	33
319	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	1.7	44
320	Meta-Analysis of Randomized Controlled Trials of Preprocedural Statin Administration for Reducing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Catheterization. American Journal of Cardiology, 2014, 114, 541-548.	1.6	44
321	Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. EuroIntervention, 2014, 10, 133-140.	3.2	55
322	Usefulness of contrast injection during balloon aortic valvuloplasty before transcatheter aortic valve replacement: a pilot study. EuroIntervention, 2014, 10, 241-247.	3.2	14
323	CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention, 2014, 10, 739-745.	3.2	85
324	Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention, 2014, 9, 1342-1349.	3.2	50

#	Article	IF	CITATIONS
325	Acute coronary syndrome due to early multiple and complete fractures in sirolimusâ€eluting stent: A case report and brief literature review. Catheterization and Cardiovascular Interventions, 2013, 81, 52-56.	1.7	5
326	Predictive Factors, Management, and Clinical Outcomes of Coronary Obstruction Following Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 62, 1552-1562.	2.8	502
327	Optical coherence tomography guided in-stent thrombus removal in patients with acute coronary syndromes. International Journal of Cardiovascular Imaging, 2013, 29, 989-996.	1.5	19
328	Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1585-1595.	2.8	702
329	Left ventricular reverse remodeling after transcatheter aortic valve implantation: a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 39.	3.3	29
330	Prevalence of renal artery stenosis in patients undergoing cardiac catheterization. Internal and Emergency Medicine, 2013, 8, 401-408.	2.0	11
331	Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 1718-1719.	1.7	6
332	30days and midterm outcomes of patients undergoing percutaneous replacement of aortic valve according to their renal function: A multicenter study. International Journal of Cardiology, 2013, 167, 1514-1518.	1.7	52
333	Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients. International Journal of Cardiology, 2013, 167, 2995-2999.	1.7	4
334	Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: Results from an intermediate risk propensity-matched population of the Italian OBSERVANT study. International Journal of Cardiology, 2013, 167, 1945-1952.	1.7	101
335	Cender-related differences of diabetic patients undergoing percutaneous coronary intervention with drug-eluting stents: A real-life multicenter experience. International Journal of Cardiology, 2013, 168, 139-143.	1.7	12
336	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
337	Paravalvular leak after CoreValve implantation in the Italian Registry: Predictors and impact on clinical outcome. International Journal of Cardiology, 2013, 168, 5088-5089.	1.7	11
338	Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 959-973.	1.5	17
339	Paclitaxel versus sirolimus eluting stents in diabetic patients: Does stent type and/or stent diameter matter?: Longâ€term clinical outcome of 2,429â€patient multicenter registry. Catheterization and Cardiovascular Interventions, 2013, 81, 80-89.	1.7	15
340	Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques — Insights from optical coherence tomography. International Journal of Cardiology, 2013, 170, e33-e35.	1.7	3
341	Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions. Interventional Cardiology Clinics, 2013, 2, 635-642.	0.4	2
342	Results Differ Between Transaortic and Open Surgical Aortic Valve Replacement in Women. Annals of Thoracic Surgery, 2013, 96, 1336-1342.	1.3	10

#	Article	IF	CITATIONS
343	Impact of coronary artery disease in elderly patients undergoing transcatheter aortic valve implantation: Insight from the Italian CoreValve Registry. International Journal of Cardiology, 2013, 167, 943-950.	1.7	73
344	Incorporating Glomerular filtration rate or creatinine clearance by the modification of diet in renal disease equation or the Cockcroft–Gault equations to improve the Global Accuracy of the Age, Creatinine, Ejection Fraction [ACEF] score in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 396-402.	1.7	23
345	One year clinical outcomes in patients with severe aortic stenosis and left ventricular systolic dysfunction undergoing transcatheteter aortic valve implantation: Results from the Italian CoreValve Registry. International Journal of Cardiology, 2013, 168, 4877-4879.	1.7	3
346	Valve rupture after balloon aortic valvuloplasty successfully managed with emergency transcatheter aortic valve implantation. International Journal of Cardiology, 2013, 168, e13-e14.	1.7	4
347	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. Interventional Cardiology Clinics, 2013, 2, 573-583.	0.4	Ο
348	First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: Insights from optical coherence tomography. International Journal of Cardiology, 2013, 168, 4490-4491.	1.7	13
349	One- and Twelve-Month Safety and Efficacy Outcomes of Patients Undergoing Edge-to-Edge Percutaneous Mitral Valve Repair (from the GRASP Registry). American Journal of Cardiology, 2013, 111, 1482-1487.	1.6	131
350	Authors' Reply. Journal of the American Society of Echocardiography, 2013, 26, 219-220.	2.8	0
351	EuroSCORE II Versus Additive and Logistic EuroSCORE in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2013, 112, 323-329.	1.6	14
352	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. American Heart Journal, 2013, 165, 133-142.	2.7	30
353	Causes of Death in Patients ≥75 Years of Age With Non–ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2013, 112, 1-7.	1.6	34
354	Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. International Journal of Cardiology, 2013, 167, 1237-1241.	1.7	79
355	Comparison of Variables in Men Versus Women Undergoing Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis (from Italian Multicenter CoreValve Registry). American Journal of Cardiology, 2013, 111, 88-93.	1.6	64
356	Successful retrograde recanalization of chronic total coronary occlusion with multiple bioresorbable vascular scaffolds (â€~full polymer jacket'): initial experience and rationale. European Heart Journal, 2013, 34, 2925-2925.	2.2	9
357	Transcatheter aortic valve implantation for severe regurgitation in native and degenerated bioprosthetic aortic valves. Catheterization and Cardiovascular Interventions, 2013, 81, 864-870.	1.7	20
358	Feasibility, Reproducibility, and Agreement between Different Speckle Tracking Echocardiographic Techniques for the Assessment of Longitudinal Deformation. BioMed Research International, 2013, 2013, 1-9.	1.9	9
359	Interplay Between Mitral Regurgitation and Transcatheter Aortic Valve Replacement With the CoreValve Revalving System. Circulation, 2013, 128, 2145-2153.	1.6	113
360	Inaccuracy of available surgical risk scores to predict outcomes after transcatheter aortic valve replacement. Journal of Cardiovascular Medicine, 2013, 14, 894-898.	1.5	48

#	Article	IF	CITATIONS
361	Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving System. Circulation, 2013, 127, 1300-1307.	1.6	141
362	Anatomical and Procedural Features Associated With Aortic Root Rupture During Balloon-Expandable Transcatheter Aortic Valve Replacement. Circulation, 2013, 128, 244-253.	1.6	476
363	Response to Letter Regarding Article, "Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving Systemâ€: Circulation, 2013, 128, e444.	1.6	0
364	Mitral Flexible Annuloplasty Band Displacement: The Role of Three-Dimensional Echocardiography. Echocardiography, 2013, 30, E56-E58.	0.9	0
365	Usefulness of the logistic clinical SYNTAX score for predicting 1â€year mortality in patients undergoing percutaneous coronary intervention of the left main coronary artery. Catheterization and Cardiovascular Interventions, 2013, 82, E446-52.	1.7	6
366	Paclitaxel―and sirolimusâ€eluting stents in older patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2013, 81, 1117-1124.	1.7	8
367	Objectifying the impact of incomplete revascularization by repeat angiographic risk assessment with the residual SYNTAX score after left main coronary artery percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, 333-340.	1.7	32
368	Three-dimensional echocardiographic and surgical findings in mitral mechanical valve dysfunction. Journal of Cardiovascular Medicine, 2013, 14, 317-318.	1.5	0
369	Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs). Recent Patents on Cardiovascular Drug Discovery, 2013, 8, 2-9.	1.5	5
370	Long-term results after percutaneous closure of atrial septal defect: Cardiac remodeling and quality of life. Journal of Cardiovascular Echography, 2013, 23, 53.	0.4	5
371	Gender differences in patients undergoing TAVI: a multicentre study. EuroIntervention, 2013, 9, 367-372.	3.2	57
372	Pre-defining optimal C-arm position for TAVI with CT-scan using free software. EuroIntervention, 2013, 9, 878-879.	3.2	2
373	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	3.2	2
374	Accessory aortic-valve tissue as a cause of severe aortic regurgitation: intra-operative finding. European Journal of Cardio-thoracic Surgery, 2012, 41, 452-453.	1.4	1
375	Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. European Heart Journal, 2012, 33, 969-976.	2.2	265
376	Percutaneous Treatment of Left Side Cardiac Valves. , 2012, , .		2
377	Novel drugs for oral anticoagulation pharmacotherapy. Expert Review of Cardiovascular Therapy, 2012, 10, 473-488.	1.5	6
378	Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of Cardiovascular Medicine, 2012, 13, 162-163.	1.5	3

CORRADO TAMBURINO

#	Article	IF	CITATIONS
379	Renal artery diameter, renal function and resistant hypertension in patients with low-to-moderate renal artery stenosis. Journal of Hypertension, 2012, 30, 600-607.	0.5	20
380	Transcatheter Aortic Valve Implantation in Patients With Mitral Prosthesis. Journal of the American College of Cardiology, 2012, 60, 1841-1842.	2.8	18
381	Left Cardiac Chambers Reverse Remodeling after Percutaneous Mitral Valve Repair with the MitraClip System. Journal of the American Society of Echocardiography, 2012, 25, 1099-1105.	2.8	45
382	Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. European Heart Journal, 2012, 33, 2513-2520.	2.2	349
383	Accuracy of intracardiac echocardiography for aortic root assessment in patients undergoing transcatheter aortic valve implantation. American Heart Journal, 2012, 163, 684-689.	2.7	15
384	A focused update on emerging prognostic determinants in distal left main percutaneous coronary intervention. International Journal of Cardiology, 2012, 160, 4-7.	1.7	5
385	Quality of life following percutaneous mitral valve repair with the MitraClip System. International Journal of Cardiology, 2012, 155, 194-200.	1.7	44
386	Unraveling the EXCEL: Promises and challenges of the next trial of left main percutaneous coronary intervention. International Journal of Cardiology, 2012, 156, 1-3.	1.7	24
387	Does the SYNTAX score get on your nerves? Practical considerations on how and when avoiding it to maximize its usefulness with no waste of time. International Journal of Cardiology, 2012, 159, 165-168.	1.7	7
388	Increasing CHADS2 scores may attenuate the benefit of novel oral anticoagulants versus warfarin in reducing intracranial bleeding. International Journal of Cardiology, 2012, 161, 176-177.	1.7	5
389	Transient Impairment of Vasomotion Function After Successful Chronic Total Occlusion Recanalization. Journal of the American College of Cardiology, 2012, 59, 711-718.	2.8	90
390	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
391	Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study. JACC: Cardiovascular Interventions, 2012, 5, 1209-1219.	2.9	82
392	Comparative One-Year Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients <75 Versus ≥75 Years With Unprotected Left Main Disease (from the) Tj ETQq() 0106rgBT	/Oværlock 10
393	Mitral Valve Diseases. , 2012, , 15-135.		0
394	Aortic Valve Disease. , 2012, , 137-268.		0
395	Transcatheter Valve Treatment: Periprocedural Management. , 2012, , 313-331.		Ο

A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. Journal of the American College of Cardiology, 2012, 60, 2473-2480.

2.8 280

23

#	Article	IF	CITATIONS
397	Core valve embolization: Technical challenges and management. Catheterization and Cardiovascular Interventions, 2012, 79, 777-782.	1.7	12
398	Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 189-195.	1.3	58
399	Rotational atherectomy: A "survivor―in the drug-eluting stent era. Cardiovascular Revascularization Medicine, 2012, 13, 185-192.	0.8	27
400	Comparison of Complications and Outcomes to One Year of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis. American Journal of Cardiology, 2012, 109, 1487-1493.	1.6	62
401	Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial. American Journal of Kidney Diseases, 2012, 60, 39-46.	1.9	45
402	Selection of Patient for Cardiac Resynchronization Therapy: Role of QT Corrected Dispersion. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 850-855.	1.2	3
403	Postinfarction Ventricular Septal Defect: The Role of Threeâ€Dimensional Echocardiography. Echocardiography, 2012, 29, E107-9.	0.9	5
404	Percutaneous Mitral Valve Repair in Patients with Prior Cardiac Surgery. Journal of Cardiac Surgery, 2012, 27, 295-298.	0.7	6
405	Miniâ€STAR as bailâ€out strategy for percutaneous coronary intervention of chronic total occlusion. Catheterization and Cardiovascular Interventions, 2012, 79, 30-40.	1.7	77
406	Early―and midâ€ŧerm outcomes of transcatheter aortic valve implantation in patients with logistic EuroSCORE less than 20%: A comparative analysis between different risk strata. Catheterization and Cardiovascular Interventions, 2012, 79, 132-140.	1.7	33
407	Transcatheter aortic bioprosthesis dislocation: technical aspects and midterm follow-up. EuroIntervention, 2012, 7, 1285-1292.	3.2	36
408	Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry. EuroIntervention, 2012, 7, 1062-1068.	3.2	9
409	Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) score. EuroIntervention, 2012, 8, 359-367.	3.2	27
410	Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro lâ€MInfarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention, 2012, 8, 823-829.	3.2	325
411	The European experience since CE approval. , 2012, , 121-125.		Ο
412	How should I treat a massive thrombus embolisation in the left coronary artery during chronic total occlusion revascularisation?. EuroIntervention, 2012, 8, 866-875.	3.2	0
413	3-year outcomes of self-expanding Corevalve prosthesis - The Italian Registry. Annals of Cardiothoracic Surgery, 2012, 1, 182-4.	1.7	5
414	Detection of very early stent healing after primary angioplasty: an optical coherence tomographic observational study of chromium cobaltum and first-generation drug-eluting stents. The DETECTIVE Study. Heart, 2011, 97, 1841-1846.	2.9	25

#	Article	IF	CITATIONS
415	The Valve-in-Valve Technique for Treatment of Aortic Bioprosthesis Malposition. Journal of the American College of Cardiology, 2011, 57, 1062-1068.	2.8	96
416	Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 1426-1432.	2.8	185
417	Transcatheter Valve-in-Valve Implantation Using CoreValve Revalving System for Failed Surgical Aortic Bioprostheses. JACC: Cardiovascular Interventions, 2011, 4, 1228-1234.	2.9	62
418	Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis. Circulation, 2011, 123, 299-308.	1.6	1,044
419	Integrating the Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score into practice: Use, pitfalls, and new directions. American Heart Journal, 2011, 161, 462-470.	2.7	33
420	Routine versus selective coronary artery bypass for left main coronary artery revascularization: The appraise a customized strategy for left main revascularization (CUSTOMIZE) study. International Journal of Cardiology, 2011, 150, 307-314.	1.7	1
421	Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology, 2011, 146, 242-243.	1.7	2
422	A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in left main patients with intermediate Global Risk. International Journal of Cardiology, 2011, 150, 116-117.	1.7	4
423	Daytime sleepiness does not predict sleep apnoea in patients with coronary artery disease. International Journal of Cardiology, 2011, 151, 248-250.	1.7	9
424	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thrombosis and Haemostasis, 2011, 106, 1149-1157.	3.4	29
425	Novel drug-eluting stents in the treatment of de novo coronary lesions. Vascular Health and Risk Management, 2011, 7, 103.	2.3	18
426	Head-to-head comparison of early vessel healing by optical coherence tomography after implantation of different stents in the same patient. Journal of Cardiovascular Medicine, 2011, 12, 328-333.	1.5	10
427	Impact of diabetes mellitus on long-term follow-up of percutaneous coronary intervention based on clinical presentation of coronary artery disease. Journal of Cardiovascular Medicine, 2011, 12, 405-410.	1.5	8
428	Functional and clinical implications of cardiac resynchronization therapy on outcomes of diabetic patients with heart failure. Journal of Cardiovascular Medicine, 2011, 12, 396-400.	1.5	5
429	The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interventional Cardiology, 2011, 3, 451-460.	0.0	1
430	Does Occlusion Duration Influence Procedural and Clinical Outcome of Patients Who Underwent Percutaneous Coronary Intervention for Chronic Total Occlusion?. Journal of Interventional Cardiology, 2011, 24, 223-231.	1.2	13
431	Long-Term Clinical and Angiographic Results of Sirolimus-Eluting Stent in Complex Coronary Chronic Total Occlusion Revascularization: The SECTOR Registry. Journal of Interventional Cardiology, 2011, 24, 426-436.	1.2	31
432	Comparison of One-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery Disease and Acute Coronary Syndromes (from the CUSTOMIZE Registry). American Journal of Cardiology, 2011, 108, 355-359.	1.6	39

#	Article	IF	CITATIONS
433	Dual Antiplatelet Therapy Versus Aspirin Alone in Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2011, 108, 1772-1776.	1.6	231
434	Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clinical Research in Cardiology, 2011, 100, 403-411.	3.3	22
435	ls intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry. Clinical Research in Cardiology, 2011, 100, 1021-1028.	3.3	38
436	Epidemiology and clinical impact of different anatomical phenotypes of the left main coronary artery. Heart and Vessels, 2011, 26, 138-144.	1.2	10
437	Global Risk Classification and Clinical SYNTAX (Synergy between Percutaneous Coronary Intervention) Tj ETQq1 1 Revascularization. JACC: Cardiovascular Interventions, 2011, 4, 287-297.	0.784314 2.9	1 rgBT /Over 119
438	Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 82.	3.3	34
439	Aortic valve perforation during aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2011, 77, 876-880.	1.7	11
440	Validating the EXCEL hypothesis: A propensity score matched 3â€year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score â‰ 9 2. Catheterization and Cardiovascular Interventions, 2011, 77, 936-943.	1.7	25
441	Percutaneous treatment of aortic stenosis and mitral regurgitation in the same patient. Catheterization and Cardiovascular Interventions, 2011, 78, 650-655.	1.7	19
442	Transcatheter aortic valve implantation for severe aortic regurgitation in a stentless bioprosthetic valve with the core valve revalving system—Technical tips and role of the accutrak system. Catheterization and Cardiovascular Interventions, 2011, 78, 485-490.	1.7	10
443	Trans catheter aortic valve implantation with core valve revalving system in uncoiled (horizontal) aorta. overcoming anatomical and technical challenges for successful deployment. Catheterization and Cardiovascular Interventions, 2011, 78, 964-969.	1.7	19
444	The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2011, 12, 1075-1086.	1.8	0
445	Reference Renal Artery Diameter Is a Stronger Predictor of Contrast-Induced Nephropathy than Chronic Kidney Disease in Patients with High Cardiovascular Risk. Nephron Extra, 2011, 1, 38-44.	1.1	4
446	Infective endocarditis in mitral mechanical prosthesis: the role of three-dimensional transoesophageal echocardiography. European Heart Journal Cardiovascular Imaging, 2011, 12, 801-801.	1.2	0
447	Impact of Drug-Eluting Stents and Diabetes Mellitus in Patients With Coronary Bifurcation Lesions: A Survey From the Italian Society of Invasive Cardiology. Circulation: Cardiovascular Interventions, 2011, 4, 72-79.	3.9	6
448	Quality-of-life in elderly patients one year after transcatheter aortic valve implantation for severe aortic stenosis. EuroIntervention, 2011, 7, 573-579.	3.2	48
449	Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]. Recent Patents on Drug Delivery and Formulation, 2010, 4, 18-22.	2.1	10
450	Sirolimus versus paclitaxel-eluting stents in small coronary vessels: long-term outcomes from a single-center registry. Journal of Cardiovascular Medicine, 2010, 11, 365-368.	1.5	7

#	Article	IF	CITATIONS
451	Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design. Journal of Cardiovascular Medicine, 2010, 11, 53-58.	1.5	5
452	A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. Journal of Cardiovascular Medicine, 2010, 11, 299-309.	1.5	3
453	ClearWayRX System to reduce intracoronary thrombus in patients with acute coronary syndromes according to Optical Coherence Tomography after Abciximab Intracoronary Local infusion trial (COCTAIL): study rationale and design. Journal of Cardiovascular Medicine, 2010, 11, 130-136.	1.5	11
454	Transcatheter mitral valve repair with the MitraClip [®] system. Interventional Cardiology, 2010, 2, 785-793.	0.0	0
455	Elective coronary stent patients: preinterventional functional status and clinical-instrumental assessment. Heart and Vessels, 2010, 25, 82-86.	1.2	3
456	Mid-term follow-up after retrograde recanalization of chronically occluded saphenous vein graft. Clinical Research in Cardiology, 2010, 99, 257-259.	3.3	1
457	Management of percutaneous self-expanding bioprosthesis migration. Clinical Research in Cardiology, 2010, 99, 673-676.	3.3	8
458	Treatment of a large thrombus containing lesion with the MGuardâ,,¢ protective net coronary stent system: optical coherence tomographic evidence of complete plaque sealing. Clinical Research in Cardiology, 2010, 99, 605-608.	3.3	2
459	Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. American Journal of Cardiology, 2010, 105, 174-178.	1.6	11
460	Feasibility of percutaneous transcatheter mitral valve repair with the MitraClip® system using conscious sedation. Catheterization and Cardiovascular Interventions, 2010, 75, 1137-1140.	1.7	24
461	Management of implant failure during transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 76, 440-449.	1.7	54
462	Postprocedural management of patients after transcatheter aortic valve implantation procedure with selfâ€expanding bioprosthesis. Catheterization and Cardiovascular Interventions, 2010, 76, 757-766.	1.7	37
463	Plaque Distribution Patterns in Distal Left Main Coronary Artery to Predict Outcomes After Stent Implantation. JACC: Cardiovascular Interventions, 2010, 3, 624-631.	2.9	33
464	Local Delivery Versus Intracoronary Infusion of Abciximab in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2010, 3, 928-934.	2.9	73
465	A Novel 3â€D Reconstruction System for the Assessment of Bifurcation Lesions Treated by the Miniâ€Crush Technique. Journal of Interventional Cardiology, 2010, 23, 46-53.	1.2	15
466	Recanalization of Complex Coronary Chronic Total Occlusions Using Highâ€Frequency Vibrational Energy CROSSER Catheter as Firstâ€Line Therapy: A Single Center Experience. Journal of Interventional Cardiology, 2010, 23, 130-138.	1.2	15
467	Prognostic Value of Exercise Myocardial Scintigraphy in Patients with Coronary Chronic Total Occlusions. Journal of Interventional Cardiology, 2010, 23, 139-148.	1.2	29
468	TAVI as a threat to surgical practice: "much ado about nothing" or "the quiet before the storm"?. Heart, 2010, 96, 1609-1610.	2.9	6

#	Article	IF	CITATIONS
469	Retrograde approach for chronic total occlusion percutaneous revascularization. Interventional Cardiology, 2010, 2, 391-403.	0.0	4
470	Anterograde techniques for percutaneous revascularization of chronic total coronary occlusions. Interventional Cardiology, 2010, 2, 377-390.	0.0	9
471	Transcatheter aortic valve implantation: what has been done and what is going to be done. Future Cardiology, 2010, 6, 83-95.	1.2	8
472	Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. European Heart Journal, 2010, 31, 1382-1389.	2.2	230
473	Retrograde recanalization of an in-stent ostial chronically occluded right coronary artery. International Journal of Cardiology, 2010, 142, 304-306.	1.7	1
474	Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention. International Journal of Cardiology, 2010, 145, 299-300.	1.7	0
475	Percutaneous aortic valve replacement in a 65-year old patient with thalassemia intermedia: A case report. Transfusion and Apheresis Science, 2010, 43, 189-192.	1.0	0
476	EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. American Heart Journal, 2010, 159, 103-109.	2.7	108
477	Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: Do we really need it?. American Heart Journal, 2010, 159, 98-102.	2.7	21
478	Response to: SYNTAX score and left main stenting: Do we need clinical variables to predict outcomes?. American Heart Journal, 2010, 159, e27.	2.7	0
479	Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: Results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-CISE) Italian Multicenter Registry on Bifurcations (I-BICIS). American Heart Journal, 2010, 160, 535-542.e1.	2.7	40
480	Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions. American Heart Journal, 2010, 160, 973-978.	2.7	19
481	Percutaneous Treatment of Left Side Cardiac Valves. , 2010, , .		2
482	Clinical Development of Selective Anticoagulants: A State of the Art. Reviews on Recent Clinical Trials, 2010, 5, 85-93.	0.8	3
483	Impact of right coronary artery disease on mortality in patients undergoing percutaneous coronary intervention of unprotected left main coronary artery disease. EuroIntervention, 2010, 6, 454-460.	3.2	9
484	Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention, 2010, 5, 703-708.	3.2	27
485	Sex-related differences in patients undergoing percutaneous unprotected left main stenting. EuroIntervention, 2010, 5, 795-800.	3.2	18
486	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14

#	Article	IF	CITATIONS
487	Transcatheter Valve Treatment: Peri-procedural Management. , 2010, , 255-272.		0
488	Mitral Valve Disease. , 2010, , 15-124.		0
489	Aortic Valve Disease. , 2010, , 125-214.		0
490	Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to high-risk transcatheter aortic valve implantation. Journal of Invasive Cardiology, 2010, 22, 161-6.	0.4	40
491	Consequences of underexpansion of a percutaneous aortic valve bioprosthesis. Journal of Invasive Cardiology, 2010, 22, E86-9.	0.4	6
492	Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry. European Heart Journal, 2009, 30, 1171-1179.	2.2	50
493	Evolution of stents: past, present and future. Expert Review of Cardiovascular Therapy, 2009, 7, 443-446.	1.5	8
494	Quality of life assessment after percutaneous aortic valve implantation. European Heart Journal, 2009, 30, 1790-1796.	2.2	84
495	Usefulness of the SYNTAX Score for Predicting Clinical Outcome After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2009, 2, 302-308.	3.9	196
496	Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology. European Heart Journal, 2009, 30, 2087-2094.	2.2	112
497	Comparison of Drug-Eluting Stents and Bare-Metal Stents for the Treatment of Unprotected Left Main Coronary Artery Disease in Acute Coronary Syndromes. American Journal of Cardiology, 2009, 103, 187-193.	1.6	36
498	Optical Coherence Tomographic Results at Six-Month Follow-Up Evaluation of the CATANIA Coronary Stent System With NanoThin Polyzene-F Surface Modification (from the Assessment of The LAtest) Tj ETQq0 0 0 1551-1555.	rgBT /Ove	rlock 10 Tf 5
499	Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease. Cardiovascular Revascularization Medicine, 2009, 10, 216-220.	0.8	4
500	Real world safety and efficacy of the Janus tacrolimusâ€eluting stent: Longâ€ŧerm clinical outcome and angiographic findings from the tacrolimusâ€eluting stent (TEST) registry. Catheterization and Cardiovascular Interventions, 2009, 73, 243-248.	1.7	23
501	Longâ€ŧerm clinical outcomes after drugâ€eluting stent implantation in unprotected left main coronary artery disease. Catheterization and Cardiovascular Interventions, 2009, 73, 291-298.	1.7	22
502	Longâ€ŧerm clinical benefit of drugâ€eluting stents over bareâ€metal stents in diabetic patients with <i>de novo</i> left main coronary artery disease: Results from a realâ€world multicenter registry. Catheterization and Cardiovascular Interventions, 2009, 73, 310-316.	1.7	5
503	The valveâ€inâ€valve technique: Transcatheter treatment of aortic bioprothesis malposition. Catheterization and Cardiovascular Interventions, 2009, 73, 713-716.	1.7	42
504	Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device. Catheterization and Cardiovascular Interventions, 2009, 74, 607-614.	1.7	22

#	Article	IF	CITATIONS
505	Percutaneous closure of left atrial appendage to prevent embolic events in highâ€risk patients with chronic atrial fibrillation. Catheterization and Cardiovascular Interventions, 2009, 74, 217-222.	1.7	31
506	A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. Clinical Research in Cardiology, 2009, 98, 240-248.	3.3	12
507	Spontaneous coronary artery dissection: a report of two atypical cases. Heart and Vessels, 2009, 24, 380-384.	1.2	1
508	Early Conduction Disorders Following Percutaneous Aortic Valve Replacement. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S126-30.	1.2	71
509	Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions. JACC: Cardiovascular Interventions, 2009, 2, 185-194.	2.9	32
510	First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2009, 2, 197-204.	2.9	30
511	Usefulness of SYNTAX Score to Select Patients With Left Main Coronary Artery Disease to Be Treated With Coronary Artery Bypass Graft. JACC: Cardiovascular Interventions, 2009, 2, 731-738.	2.9	150
512	Current management of unprotected left main coronary artery disease: Run-in survey of the RITMO (Registro Italiano sul Trattamento del tronco coMune non protettO) study. International Journal of Cardiology, 2009, 137, 74-75.	1.7	1
513	Temporal Pattern of Ischemic Events in Relation to Dual Antiplatelet Therapy in Patients With Unprotected Left Main Coronary Artery Stenosis Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2009, 53, 1176-1181.	2.8	16
514	Revascularization for Unprotected Left Main Disease. Journal of the American College of Cardiology, 2009, 54, 1576-1588.	2.8	49
515	Transesophageal echocardiography and transcranial color Doppler: independent or complementary diagnostic tests for cardiologists in the detection of patent foramen ovale?. Journal of Cardiovascular Medicine, 2009, 10, 143-148.	1.5	13
516	Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry. Journal of Cardiovascular Medicine, 2009, 10, 322-329.	1.5	3
517	Transcranial color Doppler is essential to quantify right to left shunt severity. Journal of Cardiovascular Medicine, 2009, 10, 890.	1.5	1
518	Long-term follow-up after drug eluting stent implantation in left main trifurcations. EuroIntervention, 2009, 5, 432-437.	3.2	9
519	Comparison of optical coherence tomography and intravascular ultrasound for the assessment of in-stent tissue coverage after stent implantation. EuroIntervention, 2009, 5, 538-543.	3.2	54
520	Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology, 2009, 22, 13-6.	2.0	25
521	Procedural success and 30-day clinical outcomes after percutaneous aortic valve replacement using current third-generation self-expanding CoreValve prosthesis. Journal of Invasive Cardiology, 2009, 21, 93-8.	0.4	34
522	Treatment of severe regurgitation of stentless aortic valve prosthesis with a self-expandable biological valve. Journal of Invasive Cardiology, 2009, 21, E51-4.	0.4	12

#	Article	IF	CITATIONS
523	Long-term outcomes comparison of different types of DES in elderly patients from a real-world experience. Journal of Invasive Cardiology, 2009, 21, 330-3.	0.4	5
524	Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2008, 72, 448-456.	1.7	57
525	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33
526	Two-Year Clinical Outcome With Drug-Eluting Stents Versus Bare-Metal Stents in a Real-World Registry of Unprotected Left Main Coronary Artery Stenosis from the Italian Society of Invasive Cardiology. American Journal of Cardiology, 2008, 102, 1463-1468.	1.6	57
527	Percutaneous coronary implantation of sirolimus-eluting stents in unselected patients and lesions: Clinical results and multiple outcome predictors. American Heart Journal, 2008, 156, 871-878.	2.7	5
528	Impact of Bifurcation Technique on 2-Year Clinical Outcomes in 773 Patients With Distal Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2008, 1, 185-192.	3.9	108
529	Pursuing the goal to improve downstream myocardial tissue perfusion. European Heart Journal, 2008, 30, 750-751.	2.2	1
530	Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study. Diabetes Care, 2008, 31, 15-19.	8.6	38
531	Early discharge in acute myocardial infarction after clinical and angiographic risk assessment. Journal of Cardiovascular Medicine, 2008, 9, 858-861.	1.5	5
532	Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients. Journal of Cardiovascular Medicine, 2008, 9, 161-168.	1.5	6
533	A prospective multicentre observational study on the management of unprotected left main coronary artery disease: rationale and design of the Registro Italiano sul Trattamento del tronco comune non protetto study. Journal of Cardiovascular Medicine, 2008, 9, 826-830.	1.5	1
534	Steroid-eluting stents in patients with acute coronary syndrome: the Dexamethasone Eluting Stent Italian REgistry. Heart, 2007, 93, 598-600.	2.9	26
535	Late Device Dislodgement After Percutaneous Closure of Mitral Prosthesis Paravalvular Leak With Amplatzer Muscular Ventricular Septal Defect Occluder. Circulation, 2007, 115, e208-10.	1.6	25
536	Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. Journal of Cardiovascular Medicine, 2007, 8, 782-791.	1.5	4
537	S100B protein blood concentrations in pulmonary and systemic circulation: Correlations with oxygenation status and sampling modalities. Clinica Chimica Acta, 2007, 380, 243-244.	1.1	1
538	Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension. International Journal of Cardiology, 2007, 116, 427-429.	1.7	23
539	Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. International Journal of Cardiology, 2007, 117, 349-354.	1.7	37
540	Early restenosis after drug-eluting stent implantation: A putative role for platelet activation. Canadian Journal of Cardiology, 2007, 23, 57-59.	1.7	7

#	Article	IF	CITATIONS
541	Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: A multicenter prospective registry of 150 consecutive patients. Catheterization and Cardiovascular Interventions, 2007, 69, 416-424.	1.7	38
542	Long-term outcomes of bifurcation lesions after implantation of drug-eluting stents with the "mini-crush technique― Catheterization and Cardiovascular Interventions, 2007, 69, 976-983.	1.7	66
543	Comparison of Two Antiplatelet Regimens (Aspirin Alone Versus Aspirin + Ticlopidine or Clopidogrel) After Intracoronary Implantation of a Carbofilm-Coated Stent. American Journal of Cardiology, 2007, 99, 1062-1066.	1.6	13
544	Appraising the effectiveness and safety of paclitaxel-eluting stents in over 1,000 very high-risk patients: overall results of the Taxus in Real-life Usage Evaluation (TRUE) registry. EuroIntervention, 2007, 3, 333-339.	3.2	6
545	Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: Insights from the TRUE (Taxusâ"¢ in Real-life Usage Evaluation) Study. International Journal of Cardiology, 2006, 108, 406-407.	1.7	22
546	Which strategy should be used for acute ST-elevation myocardial infarction in patients aged more than 75 years?. Journal of Cardiovascular Medicine, 2006, 7, 388-396.	1.5	0
547	Percutaneous left atrial appendage transcatheter occlusion in patients with chronic nonvalvular atrial fibrillation: early institutional experience. Journal of Cardiovascular Medicine, 2006, 7, 569-572.	1.5	9
548	Usefulness of Exercise Myocardial Scintigraphy in Multivessel Coronary Disease After Incomplete Revascularization With Coronary Stenting. American Journal of Cardiology, 2006, 97, 207-215.	1.6	19
549	Clinical Features of Transient Left Ventricular Apical Ballooning. American Journal of Cardiology, 2006, 98, 1273-1276.	1.6	66
550	Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantationâ€. European Heart Journal, 2006, 27, 540-546.	2.2	89
551	Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions. JAMA - Journal of the American Medical Association, 2006, 295, 895.	7.4	419
552	Validation of Predictors of Intraprocedural Stent Thrombosis in the Drug-Eluting Stent Era. American Journal of Cardiology, 2005, 95, 1466-1468.	1.6	40
553	Long-Term angiographic follow-up after successful repeat balloon angioplasty for in-stent restenosis. Clinical Cardiology, 2001, 24, 334-340.	1.8	4
554	Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. American Journal of Cardiology, 2001, 88, 101-106.	1.6	73
555	Usefulness of exercise tomographic myocardial perfusion imaging for detection of restenosis after coronary stent implantation. American Journal of Cardiology, 2000, 85, 1362-1364.	1.6	28
556	Accuracy of exercise testing in the assessment of the severity of myocardial ischemia as determined by means of technetium-99m tetrofosmin SPECT scintigraphy. Journal of Nuclear Cardiology, 2000, 7, 575-583.	2.1	13
557	Accuracy of 99mTc-tetrofosmin myocardial tomography in the evaluation of coronary artery disease. Journal of Nuclear Cardiology, 1999, 6, 183-189.	2.1	27
558	A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheterization and Cardiovascular Interventions, 1999, 46, 162-168.	1.7	19

#	Article	IF	CITATIONS
559	Comparison of technetium 99m-tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. Journal of Nuclear Cardiology, 1998, 5, 56-63.	2.1	18
560	Rotational coronary atherectomy with adjunctive balloon angioplasty: Evaluation of lumen enlargement by quantitative angiographic analysis. American Heart Journal, 1997, 133, 203-209.	2.7	5
561	Histopathology of Thalassemic Heart Disease: An Endomyocardial Biopsy Study. Cardiovascular Pathology, 1997, 6, 205-211.	1.6	5
562	Predictors of short term clinical and angiographic outcome after coronary angioplasty for acute myocardial infarction. Catheterization and Cardiovascular Diagnosis, 1995, 36, 203-208.	0.3	7
563	Rotational coronary atherectomy with adjunctive balloon angioplasty for the treatment of ostial lesions. Catheterization and Cardiovascular Diagnosis, 1994, 33, 22-27.	0.3	32
564	Initial experience with the Europassâ,,¢: A new ultra-low profile monorail balloon catheter. Catheterization and Cardiovascular Diagnosis, 1994, 33, 76-79.	0.3	3
565	Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty. American Heart Journal, 1993, 126, 700-702.	2.7	44
566	Transient myocardial ischemia stimulates atrial natriuretic factor release. American Heart Journal, 1992, 123, 693-698.	2.7	28
567	Percutaneous Transluminal Coronary Angioplasty of Oversized Saphenous Coronary Bypass Grafts: 'Hugging Balloons' or Single Peripheral Dilatation Catheter Technique?. Cardiology, 1992, 80, 226-229.	1.4	0
568	Pulmonary edema during cardiac catheterization successfully treated with bolus administration of nicardipine. Cardiovascular Drugs and Therapy, 1991, 5, 495-496.	2.6	0
569	Diagnosis of left atrial thrombi in mitral valve disease by coronary arteriography. Catheterization and Cardiovascular Diagnosis, 1990, 21, 82-85.	0.3	3
570	Baseline and post-atrial pacing release of atrial natriuretic factor in mitral stenosis. American Heart Journal, 1990, 119, 97-101.	2.7	4
571	Hemodynamic parameters one and four weeks after cardiac transplantation. American Journal of Cardiology, 1989, 63, 635-637.	1.6	17
572	The role of endomyocardial biopsy in the diagnosis of cardiac involvement in systemic lupus erythematosus. Heart and Vessels, 1989, 5, 52-53.	1.2	12
573	Cardiac hydatid cyst with clinical features resembling subaortic stenosis. American Heart Journal, 1989, 117, 1385-1387.	2.7	17
574	Early and late hemodynamic evaluation after cardiac transplantation: A study of 28 cases. Journal of the American College of Cardiology, 1988, 11, 264-269.	2.8	52